UT Southwestern, Texas Health launched collaborative study to better understand COVID prevalence in DFW
On Jul. 10, 2020, researchers at UT Southwestern Medical Center and Texas Health Resources announced that they will…
Texas A&M, MD Anderson Scientists tested inhaled therapeutic to protect against COVID-19
On Jul. 8, 2020, scientists from Texas A&M University, biopharmaceutical company Pulmotect and MD Anderson Cancer Center announced…
Texas A&M researchers testing COVID-19 vaccine candidates for iBio
On Jun. 24, 2020, a team of scientists at Texas A&M University announced it is working with iBio…
Taconic Biosciences announced distribution of critical COVID-19 mouse model
On Jun. 22, 2020, Taconic Biosciences announced an exclusive agreement with the University of Texas Medical Branch at…
ViralClear opened enrollment with first patient dosing in phase II human trial of anti-viral MMPD oral solution for treatment of COVID-19
On Jun. 17, 2020, BioSig Technologies, and its subsidiary, ViralClear, announced that it had commenced patient enrollment with…
ViralClear added St David’s HealthCare to phase II trial for broad-spectrum oral anti-viral COVID-19 candidate
On Jun. 5, 2020, BioSig Technologies and its subsidiary, ViralClear Pharma, announced it had expanded its patient enrollment…
Tonix Pharma announced FUJIFILM Diosynth Biotechnologies to be nanufacturing partner for COVID-19 vaccine candidate TNX-1800
On Jun. 1, 2020, Tonix Pharmaceuticals announced an agreement whereby FUJIFILM Diosynth Biotechnologies will provide contract manufacturing and…
INOVIO COVID-19 DNA vaccine INO-4800 demonstrated robust neutralizing antibody and T cell immune responses in preclinical models
On May 20, 2020, INOVIO announced the publication of the preclinical study data for IN0-4800, its COVID-19 DNA…
Llama antibody engineered to block Coronavirus
On May 19, 2020, the NIH rported that researchers from the University of Texas, in collaboration with a…
ViralClear publishesd in F1000 research in vitro data demonstrating synergy between merimepodib and remdesivir against SARS-CoV-2, the cause of COVID-19
On May 14, 2020, BioSig Technologies announced that an article titled, ﾓThe IMPDH inhibitor merimepodib provided in combination…
Rice University COVID-19 research fund backed six new initiatives
On May 8, 2020, the Rice University COVID-19 Research Fund Oversight and Review Committee announced it had funded…
XBiotech identified ‘super bloods’ for development of True Human COVID-19 therapy
On May 1, 2020, XBiotech announced that human immune donors had been identified that can support the Company’s…
ViralClear submitted in vitro data on Merimepodib and Remdesivir synergistic activity against COVID-19 novel Coronavirus to peer-reviewed journal
On Apr. 30, 2020, BioSig Technologies announced that an article titled, ﾓThe IMPDH inhibitor merimepodib provided in combination…
Texas A&M researchers lead testing of tuberculosis vaccine to fight COVID-19
On Apr. 29, 2020, a team of Texas A&M University researchers asked hundreds of frontline medical workers to…
ViralClear published comparative in vitro data on merimepodib and remdesivir activity against COVID-19 novel Coronavirus in F1000 research
On Apr. 23, 2020, BioSig Technologies announced that an article titled, ﾓThe IMPDH inhibitor merimepodib has similar antiviral…
Bellicum completed sale of Houston facility to MD Anderson for $15 million
On Apr. 15, 2020, Bellicum Pharma announced closing of the sale of its Houston facility to The University…
Positive data generated by Biosig subsidiary ViralClear on Covid-19 Coronavirus published in bioRxiv
On Apr. 9, 2020, BioSig Technologies announced that an article titled “The IMPDH inhibitor merimepodib suppresses SARS-COV-2 replications”…
Texas A&M Researchers designed 3D-printed diffuser to treat COVID-19 patients
On Apr. 8, 2020, a team of Texas A&M University researchers led by Michael R. Moreno, in collaboration…
VGXI established pilot mRNA manufacturing capabilities
On Apr. 6, 2020, VGX announced successful implementation of new RNA production services through completion of all Phase…
Fred Hutch team launched hunt for coronavirus antibodies
On Apr. 2, 2020, a team of scientists at Fred Hutchinson Cancer Research Center in Seattle began searching…
Sorrento announced research testing agreement with University of Texas for preclinical testing of COVID-19 therapeutic product candidates
On Mar. 31, 2020, Sorrento announced it had entered into a research testing agreement with The University of…
Amneal Pharmaceuticals donated hydroxychloroquine sulfate to state of Texas
On Mar. 26, 2020, Amneal Pharma announced it had donated 1,000,000 hydroxychloroquine sulfate tablets to the Texas State…
iBio announced advancement of COVID-19 vaccine program
On Mar. 26, 2020, iBio announced that immunization studies for its SARS-CoV-2 Virus-Like Particle program (‘IBIO-200’) were proceeding…
iBio supporting AzarGen Biotechnologies’ development of a Rituximab biosimilar at Bryan, Texas facility
On Mar. 26, 2020, iBio announced that it had entered into a development agreement with AzarGen Biotechnologies. Signed…
Texas Biomed established team to study SARS-CoV-2, new coronavirus
On Feb. 24, 2020, Scientists at Texas Biomed began work on the novel coronavirus known as SARS-CoV-2. A…
NIH scientists identified atomic structure of novel Coronavirus protein
On Feb. 19, 2020, NIAID scientists working with investigators from the University of Texas at Austin identified the…
Biotechnology | Diagnostics | Life Science News | Non-Profit Research | Oncology | Therapeutics | Vaccine
The CPRIT awarded 55 new grants totaling over $78 million
On Feb. 19, 2020, Cancer Prevention & Research Institute of Texas (CPRIT) announced it had awarded 55 grants…
The Cancer Prevention and Research Institute of Texas announced it had recruited its 200th CPRIT scholar
On Jan. 27, 2020, the Cancer Prevention and Research Institute of Texas (CPRIT) announced it had recruited its…
The Cancer Prevention and Research Institute of Texas awarded 10 new recruitment grants
On Nov. 20, 2019, the Cancer Prevention and Research Institute of Texas (CPRIT) awarded 10 new recruitment grants,…
IRBM signed agreement with MD Anderson Cancer Center to generate novel immune-checkpoint monoclonal antibodies
On Sept. 9, 2019, IRBM announced the signing of a service and development agreement with The University of…